The SELECT trial revealed semaglutide significantly reduces cardiovascular events in overweight or obese adults without diabetes. Benefits appeared rapidly, even with minimal weight loss, suggesting direct heart-protective mechanisms beyond calorie reduction. This breakthrough offers a new strategy for managing heart risks in a broader patient population.
